Gossamer Bio (GOSS) Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. BLZE
7. IBM
8. NKE
9. MU
10. ACN

Go back to Gossamer Bio (GOSS) Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA

Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors

November 12, 2019 7:00 AM EST

Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation
GB1275 granted Orphan Drug Designation for the treatment of pancreatic cancer by the U.S. Food and Drug Administration
Preclinical data for GB1275 featured as cover article in July 3rd edition of Science Translational Medicine

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq:... More